EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Probiotic modulation of gut microbiota with Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 mitigates recurrent respiratory infections in children: a randomised-controlled trial

Ke Chen, Weiwei Ma, Jiayi Zhong, Ping Yang, Nianyang He, Wei Jiang, Changqi Liu

European Journal of Nutrition · 2026

DOI: 10.1007/s00394-026-03989-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Nutrition, 2026. Verfasst von Ke Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology …. Hauptthemen laut MEDLINE: Probiotics, Respiratory Tract Infections, Bifidobacterium animalis, Lactiplantibacillus plantarum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Dipro Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Recurrent respiratory tract infections (RRTIs) in children are associated with substantial morbidity and healthcare burden. Modulation of the gut microbiota via probiotics represents a potential adjunctive strategy to prevent recurrent infections. This study evaluated the efficacy and safety of Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 in children with RRTIs. METHODS: In a double-blind, randomized, placebo-controlled trial, 120 children with RRTIs received either daily probiotic supplementation (1 × 1010 CFU/day; n = 60) or placebo (n = 60) for 3 months, with a 6-month follow-up. Primary outcome was clinical efficacy; secondary outcomes included gut microbiota composition (16 S rRNA sequencing) and plasma immune biomarkers (IgA, IgG, IgM, C3, C4). RESULTS: Probiotics significantly improved clinical efficacy compared with placebo in both per-protocol [82.1% vs. 64.2%, p = 0.033] and intention-to-treat analyses [76.7% vs. 56.7%, p = 0.020]. Children in the probiotic group experienced fewer and shorter respiratory episodes, including fever, cough, and pharyngeal congestion (all p < 0.05). Probiotic supplementation increased beneficial taxa (B. breve, L. plantarum, S. salivarius, W. cetiin) and reduced potentially pathogenic taxa (Anaerostipes, Vibrio). IgG and IgM levels remained stable or decreased in the probiotic group, contrasting with increases in the placebo group, indicating a balanced humoral response. No adverse events were reported. CONCLUSIONS: Daily administration of XLTG11 and CCFM8661 for three months is safe and improves clinical outcomes in children with RRTIs, reducing new respiratory episodes and modulating gut microbiota and immune function. These findings support strain-specific probiotics as a viable adjunctive therapy in pediatric respiratory infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsRespiratory Tract InfectionsBifidobacterium animalisLactiplantibacillus plantarumGastrointestinal MicrobiomeHumansDouble-Blind MethodMaleFemaleChild, PreschoolChildRecurrenceBiomarkersInfantFeces

Stichwörter der Autor:innen

ChildrenGut microbiotaImmune modulationProbioticsRecurrent respiratory tract infections

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. kechen@uestc.edu.cn.
  • College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
  • Department of Clinical Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Child Health Care, Xindu Maternal and Child Health Care Hospital, Chengdu, China.
  • Laboratory of Microbiology, Immunology and Metabolism, Diprobio (Shanghai) Co, limited, Shanghai, China.
  • School of Exercise and Nutritional Sciences, San Diego State University, San Diego, USA.

Förderung

  • Dipro Medical Research Fund

Zitieren

APA

Chen, K., Ma, W., Zhong, J., Yang, P., He, N., Jiang, W., & Liu, C. (2026). Probiotic modulation of gut microbiota with Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 mitigates recurrent respiratory infections in children: a randomised-controlled trial. European Journal of Nutrition. https://doi.org/10.1007/s00394-026-03989-7

Vancouver

Chen K, Ma W, Zhong J, Yang P, He N, Jiang W, et al. Probiotic modulation of gut microbiota with Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 mitigates recurrent respiratory infections in children: a randomised-controlled trial. European Journal of Nutrition. 2026. doi:10.1007/s00394-026-03989-7

BibTeX
@article{Chen2026,
  author = {Chen, Ke and Ma, Weiwei and Zhong, Jiayi and Yang, Ping and He, Nianyang and Jiang, Wei and Liu, Changqi},
  title = {Probiotic modulation of gut microbiota with Bifidobacterium animalis subsp. lactis XLTG11 and Lactobacillus plantarum CCFM8661 mitigates recurrent respiratory infections in children: a randomised-controlled trial},
  journal = {European Journal of Nutrition},
  year = {2026},
  doi = {10.1007/s00394-026-03989-7}
}
Kostenlos starten →